| 1 | Dr Rita Hleihel | Blood | Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. | El Hajj H, et al | Lebanon |
| 2 | Dr Rita Hleihel | Cancer | Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia. | Nabbouh AI*, Hleihel RS*, et al | Lebanon |
| 3 | Dr Rita Hleihel | Cancers | Lenalidomide in Combination with Arsenic Trioxide: an Effective Therapy for Primary Effusion Lymphoma. | Moodad S*, El Hajj R*, Hleihel R*, et al | Lebanon |
| 4 | Dr Rita Hleihel | Front Microbiol | Mouse Models That Enhanced Our Understanding of Adult T Cell Leukemia. | 9. Moodad S, Akkouche A, Hleihel R, Darwiche N, El-Sabban M, Bazarbachi A, El Hajj H. | Lebanon |
| 5 | Dr Rita Hleihel | Genes | A Critical Review of Animal Models Used in Acute Myeloid Leukemia Pathophysiology. | 7. Skayneh H*, Jishi B*, Hleihel R, Hamieh M, Darwiche N, Bazarbachi A, El Sabban M, El Hajj H. | Lebanon |
| 6 | Dr Rita Hleihel | Mol Cancer Ther. | Antitumor Effect of the Atypical Retinoid ST1926 in Acute Myeloid Leukemia and Nanoparticle Formulation Prolongs Lifespan and Reduces Tumor Burden of Xenograft Mice. | 10. El-Houjeiri L*, Saad W*, Hayar B*, et al | Lebanon |
| 7 | Dr Rita Hleihel | Oncogene | Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells. | Kouzi F, et al | Lebanon |
| 8 | Dr Rita Hleihel | Retrovirology | The HTLV-1 oncoprotein Tax is modified by the ubiquitin related modifier 1 (Urm1). | Hleihel R, Khoshnood B, et al | Lebanon |
| 9 | Dr Celine Philippe | Biomolecules | ER Stress and Unfolded Protein Response in Leukemia: Friend, Foe or Both? | Philippe, C.*, Feral, K.*, Jaud, M.*,..., Rouault-Pierre, K., Mazzolini, L., Touriol, C. | United Kingdom |
| 10 | Dr Celine Philippe | Cancers | The PERK Branch of the Unfolded Protein Response Promotes DLL4 Expression by Activating an Alternative Translation Mechanism | Philippe, C.*, Jaud, M.*, ...Pyronnet, S., Laurell, H., & Touriol, C. | United Kingdom |
| 11 | Dr Celine Philippe | Cells | Translational Regulations in Response to Endoplasmic Reticulum Stress in Cancers | Philippe, C.*, Jaud, M.*, ..., Rouault-Pierre, K., & Touriol, C | United Kingdom |
| 12 | Dr Celine Philippe | Oncotarget | Key contribution of eIF4H-mediated translational control in tumor promotion | Vaysse, C., Philippe, C., ...Brousset, P., Prats, H., & Touriol, C | United Kingdom |
| 13 | Dr Celine Philippe | Science Signalling | PERK mediates the IRES-dependent translational activation of mRNAs encoding angiogenic growth factors after ischemic stress | Philippe, C.*, Dubrac, A.*, ...Prats, H., Brousset, P., & Touriol, C. | United Kingdom |
| 14 | Dr Ferran Nadeu | Annual Review of Pathology: Mechanisms of Disease | Genomic and epigenomic alterations in chronic lymphocytic leukemia | Nadeu F, et al. | Spain |
| 15 | Dr Ferran Nadeu | Blood | Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia | Nadeu F, et al. | Spain |
| 16 | Dr Ferran Nadeu | Blood | Genomic and epigenomic insights into the origin, pathogenesis and clinical behavior of mantle cell lymphoma subtypes | Nadeu F*, Martin-Garcia D*, et al. | Spain |
| 17 | Dr Ferran Nadeu | Blood | IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics | Nadeu F, et al. | Spain |
| 18 | Dr Ferran Nadeu | Blood | Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation | Schmidt J*, Ramis-Zaldivar JE*, Nadeu F, et al. | Spain |
| 19 | Dr Ferran Nadeu | Blood Cancer Journal | Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience | Mozas P, Nadeu F, et al. | Spain |
| 20 | Dr Ferran Nadeu | Clinical Cancer Research | Mutational landscape and tumor burden assessed by cell-free DNA in diffuse large B-cell lymphoma in a population-based study | Rivas-Delgado A*, Nadeu F*, et al. | Spain |
| 21 | Dr Ferran Nadeu | Haematologica | Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies | Delgado J, Nadeu F, et al. | Spain |
| 22 | Dr Ferran Nadeu | Haematologica | Serum monoclonal component in chronic lymphocytic leukemia: baseline correlations and prognostic impact | Mozas P*, Pineyroa JA*, Nadeu F, et al. | Spain |
| 23 | Dr Ferran Nadeu | Leukemia | Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia | Nadeu F, et al. | Spain |
| 24 | Dr Ferran Nadeu | Leukemia | Minimal spatial heterogeneity in chronic lymphocytic leukemia at diagnosis | Nadeu F, et al. | Spain |
| 25 | Dr Ferran Nadeu | NA | A complete list of my 39 publications can be found in GoogleScholar (user: Ferran Nadeu), ORCiD (0000-0003-2910-9440), or Publons (user: Ferran Nadeu). | I have listed here the 15 publications were I have participated as a first, second or third author. | Spain |
| 26 | Dr Ferran Nadeu | Nature | The U1 spliceosomal RNA is recurrently mutated in multiple cancers | Shuai S*, Suzuki H*, Diaz-Navarro A*, Nadeu F, et al. | Spain |
| 27 | Dr Ferran Nadeu | Nature Cancer | The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome | Duran-Ferrer M, Clot G, Nadeu F, et al. | Spain |
| 28 | Dr Ferran Nadeu | Nature Communications | A practical guide for mutational signature analysis in hematological malignancies | Maura F, Degasperi A, Nadeu F, et al. | Spain |
| 29 | Dr Ferran Nadeu | Nature Communications | IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms | Nadeu F, et al. | Spain |
| 30 | Mrs Anouchka Laurent | Blood Advances | Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models | Paola Rivera-Munoz*, Anouchka P. Laurent*, Aurelie Siret*, Cecile K. Lopez et al. | United States |
| 31 | Mrs Anouchka Laurent | Clinical Cancer Research | Constitutive activation of RAS/MAPK pathway cooperates with trisomy 21 and is therapeutically exploitable in Down syndrome B cell precursor leukemia | Anouchka P. Laurent, Aurélie Siret, Cathy Ignacimouttou, et al. | United States |
| 32 | Mrs Anouchka Laurent | Leukemia | Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome | Anouchka P. Laurent, Rishi S. Kotecha, Sébastien Malinge | United States |
| 33 | Mrs Anouchka Laurent | The Journal of Clinical Investigation | DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3 | Rahul S Bhansali, Malini Rammohan, Paul Lee, Anouchka P Laurent et al. | United States |
| 34 | Dr Laura Mosteo | bioRxiv (https://doi.org/10.1101/2020.10.26.350116) | Loss of erythroblasts in acute myeloid leukemia causes iron redistribution with clinical implications | Lopes M, et al. | Portugal |
| 35 | Dr Laura Mosteo | bioRxiv (https://doi.org/10.1101/2021.01.13.426554) | BRN2 is a non-canonical melanoma tumor-suppressor | Hamm M, et al. | Portugal |
| 36 | Dr Laura Mosteo | Frontiers in Cell and Developmental Biology (https://doi.org/10.3389/fcell.2021.635189) | The Dynamic Interface Between the Bone Marrow Vascular Niche and Hematopoietic Stem Cells in Myeloid Malignancy | Mosteo L, et al. | Portugal |
| 37 | Dr Laura Mosteo | Oncogene | The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression | Jessen C, et al. | Portugal |
| 38 | Dr Laura Mosteo | RSC Advances | Polarization, second-order nonlinear optical properties and electrochromism in 4H-pyranylidene chromophores with a quinoid/aromatic thiophene ring bridge | Marco BA, et al. | Portugal |
| 39 | Dr Laura Mosteo | Tetrahedron | Influence of thiazole regioisomerism on second-order nonlinear optical chromophores | Galán E, et al. | Portugal |
